StemCells, Inc. to Present at 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum

StemCells, Inc. to Present at 2012 Stem Cell Meeting on the Mesa's Investor
and Partnering Forum

NEWARK, Calif., Oct. 26, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM) announced today that President and CEO Martin McGlynn will make
a presentation on the Company's programs and operations at the 2^nd Annual
Investor and Partnering Forum during the 2012 Stem Cell Meeting on the Mesa to
be held October 29 -31. Mr. McGlynn is scheduled to speak at 10:15 a.m.
Pacific Time on Tuesday, October 30, at the Sanford Consortium for
Regenerative Medicine in La Jolla, California.

The Stem Cell Meeting on the Mesa is a three-day conference organized by the
Sanford Consortium for Regenerative Medicine, the California Institute for
Regenerative Medicine (CIRM) and the Alliance for Regenerative Medicine
(ARM).The goal of the conference is to bring together the scientific research
and business development communities in regenerative medicine to advance stem
cell science into cures for debilitating diseases and injuries. The meeting
features a nationally recognized Scientific Symposium attended by leading
scientists and researchers, as well as an Investor and Partnering Forum
designed to facilitate a bridge between academia and industry through
one-on-one meetings, furthering the translation of clinical research.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC®
cells (purified human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system disorders. In
a PhaseI clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company has shown preliminary evidence
of progressive and durable donor-derived myelination in all four patients
transplanted with HuCNS-SC cells.The Company is also conducting a Phase I/II
clinical trial in chronic spinal cord injury in Switzerland and recently
reported positive interim data for the first patient cohort.The Company has
also initiated a Phase I/II clinical trial in dry age-related macular
degeneration (AMD), and is pursuing preclinical studies in Alzheimer's
disease.StemCells also markets stem cell research products, including media
and reagents, under the SC Proven® brand.Further information about StemCells
is available at

The StemCells, Inc. logo is available at

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein.These
statements include, but are not limited to, statements regarding the clinical
development of its HuCNS-SC cells; the Company's ability to commercialize drug
discovery and drug development tools; and the future business operations of
the Company. These forward-looking statements speak only as of the date of
this news release. The Company does not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. Such statements reflect management's current views and are
based on certain assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those contemplated in such
forward-looking statements due to risks and uncertainties to which the Company
is subject, including those described under the heading "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended December 31, 2011
and in its subsequent reports on Forms 10-Q and 8-K.

CONTACT: Rodney Young
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
         Ian Stone
         Russo Partners
         (619) 308-6541

company logo
Press spacebar to pause and continue. Press esc to stop.